During the panel on precision medicine at the Quality Cancer Care Alliance (QCCA) Fall Leadership Summit, the speakers discussed testing every patient upfront with a broad molecular assessment and bringing clinical research to the patient.
During the panel on precision medicine at the Quality Cancer Care Alliance (QCCA) Fall Leadership Summit, the speakers discussed testing every patient upfront with a broad molecular assessment and bringing clinical research to the patient, said W. Michael Korn, MD, professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco, and chief medical officer of Caris Life Sciences.
Transcript
Are there any takeaways from the precision medicine panel at the Quality Cancer Care Alliance Fall Leadership Summit that you want to highlight?
Well, I think was a great session, because we looked at precision medicine from the different angles. And I was, you know—one of the areas where I feel, you know, I might be just sitting on my academic island sometimes, and might be too quick and moving in a certain direction—I felt very relieved when, you know, I proposed at this point, we should test every patient right up front, molecularly with a broad molecular assessment with the idea in mind, that that might not influence the immediate treatment that the patient receives but allows the doctor to chart out a pathway for that patient in a very individualized way. And that is driven by these molecular findings. And, you know, I think recognition that that is of great value, I think, will accelerate and optimize how precision medicine is being applied in clinical practice.
The other I think, take home message, where I think we all agree on is to bring research, especially clinical research, to the patient, instead of having the patient come to a tertiary treatment center. So, the idea of trials that are accessible to oncologists, in their private practice, where the trial can be opened for their patients, I think it's a very important step forward, because it really democratizes the whole approach.
You know, right now we have maybe 5% to 7% of all cancer patients will ever enroll into a clinical trial. That is so much information that's completely missed. So, we need to reverse this. And one way of doing it is through this is just-in-time clinical trial programs, where, you know, we have mechanisms now in place when we find a molecular mutation that's very important, we know there is a clinical trial that is specifically designed for this particular mutation. We can open this trial within 2 weeks at a doctor's practice. And by doing so we really believe we can flip this picture around and have the majority of patients participate in trials, so we learn while we’re treating.
So there will be—my prediction is that this kind of sharp boundary between your academic clinical research, and then the consumers of the results on the other side and the doctors in private practice, that that boundary will soften, and we'll turn more into action, where really we learn from every patient who is being treated.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More